Liu et al. have recently published a paper highlighting blood-derived miRNAs as possible early diagnostic biomarkers in Pancreatic Cancer by conducting a narrative review and meta-analysis titled, “Blood-Derived microRNAs for Pancreatic Cancer Diagnosis: A Narrative Review and Meta-Analysis” (Li et al., 2018). Considering the extreme aggressiveness and malignancy associated with Pancreatic Cancer, combined with its poor prognosis and survival rates, and the dependence of diagnosis on non-specific tumor biomarkers, Liu et al.'s study highlighting possible alternative biomarkers, is definitely one that is of great clinical value (Benzel and Fendrich, 2018). However there are a few issues with this study that may serve to hinder its practical clinical applicability. First and foremost, in fairness we would like to highlight that Liu and associates are not the first to attempt to determine the applicability of miRNAs as diagnostic biomarkers in Pancreatic Cancer, multiple such meta-analysis studies have been conducted and published in 2012, 2014, 2017 (and have not been cited by the authors of this study) and even in May of 2018 (Wan et al., 2012; Ding et al., 2014; Pei et al., 2017; Sun et al., 2018).